利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN107130000A 一种同时敲除KRAS基因和EGFR基因的CRISPR‑Cas9系统及其应用 有权

一种同时敲除KRAS基因和EGFR基因的CRISPR‑Cas9系统及其应用
摘要：
本发明公开一种同时敲除KRAS基因和EGFR基因的CRISPR‑Cas9系统，包括特异性靶向KRAS基因的sgRNA，对应的DNA序列如SEQ ID NO.1或/和SEQ ID NO.2所示，和特异性靶向EGFR基因的sgRNA，对应的DNA序列如SEQ ID NO.11或/和SEQ ID NO.12所示。本发明还公开了其在制备治疗癌症药物中的应用。本发明CRISPR‑Cas9系统可同时高效敲除在肺癌中高度表达的两个癌症驱动因子KRAS及EGFR，该系统操作简单，敲除效率高，有望在肺癌的治疗中得到应用。本发明系统适用于EGFR和KRAS异常表达的多种癌症。
摘要（英）：

The invention discloses a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 system capable of simultaneously knocking out KRAS genes and EGFR genes. The system comprises sgRNA for specifically targeting KRAS genes and sgRNA for specifically targeting EGFR genes, wherein a corresponding DNA sequence of the sgRNA for specifically targeting KRAS genes is shown as SEQ ID NO.1 or/and SEQ ID NO.2; and a corresponding DNA sequence of the sgRNA for specifically targeting EGFR genes is shown as SEQ ID NO.11 or/and SEQ ID NO.12. The invention further discloses application of the system in preparation of medicines for treating cancers. The CRISPR-Cas9 system disclosed by the invention is capable of simultaneously and efficiently knocking out two cancer driving factors KRAS and EGFR which are highly-expressed in lung cancer. The system is simple in operation and high in knockout efficiency and is expected to be applied to treatment of the lung cancer. The system disclosed by the invention is applicable to multiple cancers with abnormal expressions of the EGFR and KRAS.

公开/授权文献
0/0